Clinical Trial Update: A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 1-week intravenous N-acetylcysteine vs ambroxol and placebo as expectorants in adult Chinese patients with respiratory tract diseases an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Diseases

Drugs mentioned

• Ambroxol hydrochloride (Ambroxol)
• N-acetylcysteine (intravenous) (N-acetylcysteine)

Snippet

Sponsor: Zambon SpA | Conditions: Respiratory Tract Diseases, Abnormal Mucus Secretions | Phase 3 | Status: COMPLETED | Results posted: 2023-01-05